直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Federal Circuit Affirms Court of Federal Claims Decision Dismissing Suit Seeking Compensation for Cancelled Patent Claims

September 2, 2020

Authored and Edited by Zachery D. Olah; Amanda K. Murphy, Ph.D.

In Christy, Inc. v. U.S., No. 2019-1738 (Fed. Cir. Aug. 24, 2020), the Federal Circuit affirmed the decision of the Court of Federal Claims to dismiss a suit brought by a patent owner against the United States alleging that the United States owes the patent owner just compensation for the cancellation of its patent claims in an inter partes review.

Christy, Inc.’s U.S. Patent No. 7,082,640 (“the ’640 patent”) issued in 2006. Christy and its licensee, CDC Larue Industries, Inc., sued two competitors alleging infringement of the ’640 patent. One of the competitors filed two petitions for inter partes review of the ’640 patent. The PTAB cancelled the 18 challenged claims, leaving only two remaining claims. The Federal Circuit summarily affirmed the PTAB’s final written decision. Christy subsequently filed a class-action suit in the Court of Federal Claims raising, among other claims, a Fifth Amendment takings claim and an illegal exaction claim, seeking just compensation from the government for its cancelled patent claims and a refund of its USPTO fees. The government moved to dismiss all claims for lack of subject matter jurisdiction and failure to state a claim. The Court of Federal Claims dismissed each of Christy’s claims. Christy appealed.

On appeal, Christy argued that the Court of Federal Claims erred in three ways: by (1) finding that Christy failed to state a plausible Fifth Amendment takings claim; (2) finding that the court lacked subject matter jurisdiction over the illegal exaction claim; and (3) finding that Christy failed to state a plausible illegal exaction claim. The Federal Circuit, citing its decision in Golden v. United States, 955 F.3d 981 (Fed. Cir. 2020), held that Christy failed to state a plausible takings claim because the “cancellation of patent claims in [an] inter partes review cannot be a taking under the Fifth Amendment.”

Regarding Christy’s two remaining arguments, the Court noted that the government conceded that the Court of Federal Claims had jurisdiction to hear Christy’s illegal exaction claim. Thus, the Federal Circuit only had to address whether Christy stated a plausible illegal exaction claim. The Federal Circuit rejected Christy’s argument and affirmed the Court of Federal Claims, holding that the law required payment of the relevant USPTO fees regardless of any later post-issuance proceeding. The Court, noting Christy’s failure to identify any statute, regulation, or constitutional provision requiring a refund of its USPTO fees, held that the issue of whether a patent owner is entitled to a refund after cancellation of a patent in an IPR is a policy question that is best answered by Congress or the USPTO.

Tags

United States Court of Appeals for the Federal Circuit (CAFC), Patent Trial and Appeal Board (PTAB), subject matter jurisdiction

Related Practices

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Washington, DC

Contacts

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP